United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and …
United Therapeutics Corp.'s (UTHR) second quarter earnings of $1.43 per share were well above the year-ago earnings of $1.19 and the Zacks Consensus Estimate of $1.12. Higher revenues led to the improvement in earnings. The company …
Mad Money host Jim Cramer asks United Therapeutics Chairman and co-CEO Dr. Martine Rothblatt about founding the company after her daughter took ill with pulmonary hypertension, the potential for the Unituxin injection and the …
United Therapeutics Corporation (UTHR) recently filed a patent infringement lawsuit against Sandoz, Novartis’ (NVS) generic unit, which is seeking approval for its generic version of Remodulin (treprostinil; 10 mg/mL). The lawsuit has …
United Therapeut (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $129.53 to a high of $134.10. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $131.22 on volume of 293,000 …
Given up for dead just weeks ago the biotech sector is suddenly back with a vengeance. Seemingly everyone’s favorite …
Description: United Therapeutics develops and makes medicines for cardiovascular conditions, cancer and infectious diseases. Developments: Executives at United Therapeutics are hoping this year will be as good as 2004. Last year the …
NEW YORK, NY / ACCESSWIRE / July 27, 2017 / Pomerantz LLP is investigating claims on behalf of investors of …
United Therapeutics Corp Qtrly Non : United Therapeutics Corp qtrly net income, per diluted share $4.39 . Q2 earnings per share view $3.22, revenue view $395.0 million -- Thomson Reuters I/B/E/S . United Therapeutics Corporation reports …